2328 related articles for article (PubMed ID: 23383558)
1. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
3. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the immunological phenomena and relationship with clinicopathological characteristics of the tumor--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ lymphocytes in squamous cell laryngeal carcinoma. Part II.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):593-603. PubMed ID: 22252753
[TBL] [Abstract][Full Text] [Related]
5. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
[TBL] [Abstract][Full Text] [Related]
7. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
8. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy.
Yacyshyn MB; Poppema S; Berg A; MacLean GD; Reddish MA; Meikle A; Longenecker BM
Int J Cancer; 1995 May; 61(4):470-4. PubMed ID: 7538976
[TBL] [Abstract][Full Text] [Related]
9. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.
Grimm M; Feyen O; Hofmann H; Teriete P; Biegner T; Munz A; Reinert S
Tumour Biol; 2016 Mar; 37(3):3807-16. PubMed ID: 26474587
[TBL] [Abstract][Full Text] [Related]
11. CD4
Piersiala K; Farrajota Neves da Silva P; Hjalmarsson E; Kolev A; Kågedal Å; Starkhammar M; Elliot A; Marklund L; Margolin G; Munck-Wikland E; Kumlien Georén S; Cardell LO
Cancer Sci; 2021 Mar; 112(3):1048-1059. PubMed ID: 33462898
[TBL] [Abstract][Full Text] [Related]
12. Immunoregulatory molecules in patients with gestational diabetes mellitus.
Pendeloski KP; Mattar R; Torloni MR; Gomes CP; Alexandre SM; Daher S
Endocrine; 2015 Sep; 50(1):99-109. PubMed ID: 25754913
[TBL] [Abstract][Full Text] [Related]
13. Activated T lymphocytes in pre-eclampsia.
Darmochwal-Kolarz D; Saito S; Rolinski J; Tabarkiewicz J; Kolarz B; Leszczynska-Gorzelak B; Oleszczuk J
Am J Reprod Immunol; 2007 Jul; 58(1):39-45. PubMed ID: 17565546
[TBL] [Abstract][Full Text] [Related]
14. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma.
Sheu BC; Lin RH; Ho HN; Huang SC
Hum Immunol; 1997; 56(1-2):39-48. PubMed ID: 9455492
[TBL] [Abstract][Full Text] [Related]
16. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
[TBL] [Abstract][Full Text] [Related]
17. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
18. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer.
Takenoyama M; Yasumoto K; Harada M; Matsuzaki G; Ishida T; Sugimachi K; Nomoto K
Immunobiology; 1996 Jul; 195(2):140-51. PubMed ID: 8877391
[TBL] [Abstract][Full Text] [Related]
19. Immunopathogenesis of dilated cardiomyopathy. Evidence for the role of TH2-type CD4+T lymphocytes and association with myocardial HLA-DR expression.
Kuethe F; Braun RK; Foerster M; Schlenker Y; Sigusch HH; Kroegel C; Figulla HR
J Clin Immunol; 2006 Jan; 26(1):33-9. PubMed ID: 16418801
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the intracellular expression of interleukin 17 in patients with ovarian cancer].
Rogala E; Nowicka A; Bednarek W; Barczyński B; Wertel I; Zakrzewski M; Kotarski J
Ginekol Pol; 2012 Jun; 83(6):424-8. PubMed ID: 22880461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
